MANH vs PEGA

MANH exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptional ROE of 71.66%, though it lacks an Altman Z-Score for bankruptcy risk assessment. While the company has a stellar 25-quarter track record of earnings beats, the stock is currently in a severe technical downtrend, losing over 37% of its value in the last six months. The current price of $126.11 trades at a significant premium to both the Graham Number ($20.64) and the growth-based Intrinsic Value ($79.74). Despite a bullish analyst target of $208.55, the combination of slow revenue growth (5.7%) and bearish insider sentiment warrants a neutral stance until price stabilization occurs.

PEGA demonstrates exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.10. While the stock trades at a significant discount to its growth-based intrinsic value ($62.83) and analyst targets ($59.36), it is severely hindered by stagnant revenue growth of only 2.70% and an alarmingly high PEG ratio of 15.20. The divergence between strong internal efficiency (ROE 57.32%) and poor top-line growth, coupled with bearish insider selling and a 0/100 technical trend, suggests a period of consolidation or transition.